Platelet count before peripheral blood stem cell mobilization is associated with the need for plerixafor but not with the collection result
Background: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. Methods: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilizati...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
Transfusion medicine and hemotherapy
Year: 2018, Volume: 45, Issue: 1, Pages: 24-31 |
| ISSN: | 1660-3818 |
| DOI: | 10.1159/000478911 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1159/000478911 Verlag, Volltext: https://www.karger.com/Article/FullText/478911 
|
| Author Notes: | Marc-Andrea Baertsch, Katharina Kriegsmann, Petra Pavel, Thomas Bruckner, Michael Hundemer, Mark Kriegsmann, Anthony D. Ho, Hartmut Goldschmidt, Patrick Wuchter |
| Summary: | Background: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. Methods: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). Results: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 10 6 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004). Conclusion: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor. |
|---|---|
| Item Description: | Gesehen am 07.08.2019 Published online: October 4, 2017 |
| Physical Description: | Online Resource |
| ISSN: | 1660-3818 |
| DOI: | 10.1159/000478911 |